Apogee Therapeutics Stock Jumps 20% on Positive Skin Disease Drug Data

Apogee Therapeutics APGE shares surged 20% as the company announced positive 52-week maintenance data from a mid-stage study of its anti-IL-13 antibody, zumilokibart, for moderate-to-severe atopic dermatitis. The drug showed sustained efficacy, with EASI-75 responses maintained in 75% and 85% of patients on three and six-month regimens, respectively. The safety profile was favorable, with mostly mild to moderate adverse events.